Safety and tolerability of 
ADVERSE EVENTS, EVENT, ADVERSE EVENT, APPENDIX
A total of seven TEAEs were reported in five (4.9%) patients following treatment with IV lacosamide (Table Treatment‐emergent adverse events (SS‐IV)Abbreviations: IV, intravenous; SS‐IV, intravenous Safety Set; TEAE, treatment‐emergent adverse event.Medical Dictionary for Regulatory Activities Version 16.1 Preferred Term.The only TEAEs reported in two or more patients were increased blood triglycerides. One event occurred in a 10‐year‐old male who had a blood triglyceride level of 1.72 mmol/L at screening and 2.52 mmol/L at the final visit (normal range: 0.27–1.55 mmol/L). This TEAE was considered moderate in severity. The patient was taking oral lacosamide and levetiracetam at baseline and had discontinued oxcarbazepine 8 days previously. The other event occurred in a 12‐year‐old female who had a blood triglyceride level of 1.45 mmol/L at screening, 0.90 mmol/L at baseline, and 1.71 mmol/L at the final visit (normal range: 0.42–1.47 mmol/L). This TEAE was considered mild in severity. The patient was taking oral lacosamide and levetiracetam at baseline. Of note, triglyceride levels rise after eating. Patients were not required to fast prior to assessment of lipid panel.Mean values for the majority of hematology and clinical chemistry parameters remained within the normal ranges for the duration of the trial (Appendix 